Swedbank AB Lowers Stock Holdings in Avantor, Inc. (NYSE:AVTR)

Swedbank AB trimmed its holdings in shares of Avantor, Inc. (NYSE:AVTR) by 2.0% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 104,998 shares of the company’s stock after selling 2,184 shares during the period. Swedbank AB’s holdings in Avantor were worth $2,716,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the business. Cerity Partners LLC lifted its holdings in shares of Avantor by 122.6% during the third quarter. Cerity Partners LLC now owns 30,538 shares of the company’s stock valued at $790,000 after purchasing an additional 16,818 shares during the last quarter. Otter Creek Advisors LLC lifted its holdings in shares of Avantor by 75.1% during the third quarter. Otter Creek Advisors LLC now owns 213,098 shares of the company’s stock valued at $5,513,000 after purchasing an additional 91,431 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Avantor by 4.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 2,952,901 shares of the company’s stock valued at $76,392,000 after purchasing an additional 121,810 shares during the last quarter. John G Ullman & Associates Inc. purchased a new position in shares of Avantor during the third quarter valued at approximately $1,863,000. Finally, King Luther Capital Management Corp purchased a new position in shares of Avantor during the third quarter valued at approximately $207,000. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Wells Fargo & Company decreased their price objective on shares of Avantor from $30.00 to $28.00 and set an “overweight” rating for the company in a report on Monday, October 28th. Barclays decreased their price objective on shares of Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a report on Friday, October 25th. UBS Group decreased their price objective on shares of Avantor from $30.00 to $29.00 and set a “buy” rating for the company in a report on Tuesday, October 8th. Robert W. Baird decreased their price objective on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a report on Monday, October 28th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $34.00 price objective on shares of Avantor in a report on Thursday, September 26th. Three analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat.com, Avantor presently has an average rating of “Moderate Buy” and an average target price of $27.57.

Avantor Trading Up 0.1 %

Shares of AVTR stock opened at $21.04 on Thursday. Avantor, Inc. has a 1 year low of $19.59 and a 1 year high of $28.00. The firm has a fifty day moving average price of $23.53 and a 200-day moving average price of $23.78. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.54 and a quick ratio of 1.06. The company has a market cap of $14.32 billion, a price-to-earnings ratio of 45.74, a PEG ratio of 2.56 and a beta of 1.35.

Insider Activity

In other news, CAO Steven W. Eck sold 3,525 shares of the business’s stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $25.06, for a total transaction of $88,336.50. Following the completion of the sale, the chief accounting officer now owns 29,544 shares of the company’s stock, valued at $740,372.64. The trade was a 10.66 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 1.30% of the company’s stock.

Avantor Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.